DNA-based cancer drugs are widely recognised as a new frontier in the field of cancer therapy.
IGEA’s electroporation technologies are used for the delivery of the following DNA-based cancer therapies:
Cancer DNA vaccines represent a very promising strategy to induce a specific and long-lasting immune response against cancer antigens.
Pre-clinical studies on B-cell lymphosarcoma in dogs have shown that the DNA vaccine targeting the enzyme telomerase is effective in activating a tumour-specific immune response and, in combination with standard chemotherapy protocols, significantly increases the survival rate of treated animals.
They consist of the administration of nucleic acids that encode for cytokines or factors capable of modulating the immune response in order to stimulate the patient’s immune system to recognise and attack the cancer.
Numerous pre-clinical studies and preliminary results of clinical trials (phase IIb KEYNOTE-695 trial for metastatic melanoma and phase II KEYNOTE-895 trial for triple-negative breast cancer) have demonstrated that immune-modulating therapies (in particular IL-12 based therapy, TAVOTM) can be an effective solution in the control of metastatic disease. Treatment can be administered either locally, via intratumoural injections in accessible nodules, or intramuscularly with systemic therapeutic intent.
A specific DNA sequence is delivered directly into the cells in order to allow the endogenous synthesis of monoclonal antibodies to attack the tumour or increase the effectiveness of the immune system.
A pre-clinical study performed in sheep shows that electroporation is an effective method of delivering plasmids encoding for monoclonal antibodies (pOVAC, encoding for ovine anti-CEA monoclonal antibody and pOVAE, encoding for ovine anti-EGFR monoclonal antibody). EGT enables sufficient serum antibody levels to exert a therapeutic effect.
Electroporation allows DNA encoding for proteins that exert an anti-tumour therapeutic effect to be delivered into cells.
Two phase I clinical trials demonstrated the safety, feasibility and tolerability of electroporation-mediated transfer of DNA encoding for anti-angiogenic metargidin peptide (AMEP) in patients with metastatic melanoma or advanced solid tumours.